Venker Eric
SEC CIK 1801917 · EDGAR
BoughtSold
Most active insiders at ROIV, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | MANCHESTER KEITH S | Dir | — | $154.47M |
| 2 | Gold Daniel Allen | Dir | — | $147.38M |
| 3 | QVT Financial LP | Dir by Deputization | — | $147.38M |
| 4 | Sukhatme Mayukh | Pres, CIO, Dir | — | $109.13M |
| 5 | Ramaswamy Vivek | 10% | — | $105.88M |
| 6 | Venker Eric | Pres, Immunovant CEO | — | $89.77M |
| 7 | Torti Frank | Pres, Vant COB | — | $82.04M |
| 8 | Gline Matthew | CEO, Dir | — | $46.17M |
| 9 | Pulik Richard | CFO | — | $9.12M |
| 10 | Fitzgerald Meghan | Dir | — | $3.27M |
Transactions 148
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-01 21:00 | 2026-08-28 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +200.0K | 1.80M | +13% | +$770.0K |
| DMT | 2026-09-01 21:00 | 2026-08-28 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $35.77 | -200.0K | 1.60M | -11% | -$7.15M |
| 2026-08-24 21:00 | 2026-08-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | F - Tax | $36.84 | -13.9K | 1.60M | -0.9% | -$512.4K | |
| DT | 2026-07-29 21:00 | 2026-07-27 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +200.0K | 1.81M | +12% | +$770.0K |
| DT | 2026-07-29 21:00 | 2026-07-27 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $34.95 | -200.0K | 1.61M | -11% | -$6.99M |
| D | 2026-07-06 17:01 | 2026-07-01 | IMVT | Immunovant, Inc. | Venker Eric | CEO, Dir | M - OptEx | $14.46 | +92.2K | 344.0K | +37% | +$1.33M |
| D | 2026-07-06 17:01 | 2026-07-01 | IMVT | Immunovant, Inc. | Venker Eric | CEO, Dir | D - Sale to Iss | $38.14 | -86.6K | 257.4K | -25% | -$3.30M |
| D | 2026-07-06 17:01 | 2026-07-02 | IMVT | Immunovant, Inc. | Venker Eric | CEO, Dir | S - Sale+OE | $38.48 | -3,092 | 254.3K | -1% | -$119.0K |
| DT | 2026-06-26 18:13 | 2026-06-24 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +200.0K | 1.81M | +12% | +$770.0K |
| DMT | 2026-06-26 18:13 | 2026-06-24 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $33.16 | -200.0K | 1.61M | -11% | -$6.63M |
| DT | 2026-05-22 18:25 | 2026-05-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | F - Tax | $32.41 | -34.5K | 1.61M | -2% | -$1.12M |
| DT | 2026-05-22 18:25 | 2026-05-22 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +200.0K | 1.81M | +12% | +$770.0K |
| DT | 2026-05-22 18:25 | 2026-05-22 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $30.27 | -200.0K | 1.61M | -11% | -$6.05M |
| DT | 2026-04-22 18:27 | 2026-04-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +200.0K | 1.85M | +12% | +$770.0K |
| DT | 2026-04-22 18:27 | 2026-04-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $29.59 | -200.0K | 1.65M | -11% | -$5.92M |
| D | 2026-04-09 16:13 | 2026-04-07 | IMVT | Immunovant, Inc. | Venker Eric | CEO, Dir | A - Grant | $0.00 | +232.3K | 251.8K | +1,187% | $0 |
| D | 2026-04-03 16:33 | 2026-04-01 | IMVT | Immunovant, Inc. | Venker Eric | CEO, Dir | M - OptEx | $14.46 | +368.8K | 368.8K | New | +$5.33M |
| D | 2026-04-03 16:33 | 2026-04-01 | IMVT | Immunovant, Inc. | Venker Eric | CEO, Dir | D - Sale to Iss | $25.10 | -335.0K | 33.8K | -91% | -$8.41M |
| DM | 2026-04-03 16:33 | 2026-04-02 | IMVT | Immunovant, Inc. | Venker Eric | CEO, Dir | S - Sale+OE | $24.10 | -14.2K | 19.6K | -42% | -$342.9K |
| D | 2026-03-19 | 2026-03-17 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $28.24 | -200.0K | 1.65M | -11% | -$5.65M |
| D | 2026-03-19 | 2026-03-17 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +200.0K | 1.85M | +12% | +$770.0K |
| 2026-02-24 | 2026-02-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | F - Tax | $27.15 | -7,051 | 1.65M | -0.4% | -$191.4K | |
| D | 2026-02-18 | 2026-02-13 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $26.49 | -200.0K | 1.65M | -11% | -$5.30M |
| D | 2026-02-18 | 2026-02-13 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +200.0K | 1.85M | +12% | +$770.0K |
| DT | 2026-01-14 | 2026-01-12 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $21.92 | -200.0K | 1.65M | -11% | -$4.38M |
| DT | 2026-01-14 | 2026-01-12 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +200.0K | 1.85M | +12% | +$770.0K |
| DM | 2025-12-29 | 2025-12-23+ | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $22.47 | -275.0K | 1.65M | -14% | -$6.18M |
| DM | 2025-12-29 | 2025-12-23+ | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +431.7K | 1.81M | +31% | +$1.66M |
| DT | 2025-12-11 | 2025-12-09 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +200.0K | 1.70M | +13% | +$770.0K |
| DT | 2025-12-11 | 2025-12-09 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $20.85 | -200.0K | 1.50M | -12% | -$4.17M |
| 2025-11-24 | 2025-11-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | F - Tax | $20.27 | -7,051 | 1.50M | -0.5% | -$142.9K | |
| DT | 2025-11-07 | 2025-11-07 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +200.0K | 1.70M | +13% | +$770.0K |
| DT | 2025-11-07 | 2025-11-07 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $20.22 | -200.0K | 1.50M | -12% | -$4.04M |
| DMT | 2025-10-17 | 2025-10-15+ | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $16.99 | -851.4K | 1.50M | -36% | -$14.47M |
| DMT | 2025-10-17 | 2025-10-15+ | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | M - OptEx | $15.85 | +851.4K | 1.82M | +88% | +$13.49M |
| DMT | 2025-10-14 | 2025-10-09+ | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | M - OptEx | $15.85 | +125.7K | 1.53M | +9% | +$1.99M |
| DMT | 2025-10-14 | 2025-10-09+ | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $16.29 | -125.7K | 1.50M | -8% | -$2.05M |
| DMT | 2025-10-08 | 2025-10-06+ | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | M - OptEx | $8.95 | +665.2K | 1.68M | +66% | +$5.96M |
| DMT | 2025-10-08 | 2025-10-06+ | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $16.21 | -665.2K | 1.50M | -31% | -$10.78M |
| DMT | 2025-09-23 | 2025-09-19+ | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +1.56M | 2.53M | +161% | +$6.02M |
| DMT | 2025-09-23 | 2025-09-19+ | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $14.92 | -1.71M | 2.12M | -45% | -$25.52M |
| DT | 2025-08-22 | 2025-08-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +100.0K | 1.75M | +6% | +$385.0K |
| DT | 2025-08-22 | 2025-08-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $11.72 | -100.0K | 1.65M | -6% | -$1.17M |
| DT | 2025-08-22 | 2025-08-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | F - Tax | $11.72 | -7,051 | 1.65M | -0.4% | -$82.6K |
| 2025-08-01 | 2025-07-30 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | A - Grant | $0.00 | +198.4K | 1.66M | +14% | $0 | |
| DT | 2025-07-23 | 2025-07-21 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $11.52 | -100.0K | 1.46M | -6% | -$1.15M |
| DT | 2025-07-23 | 2025-07-21 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +100.0K | 1.56M | +7% | +$385.0K |
| DT | 2025-06-24 | 2025-06-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | M - OptEx | $3.85 | +100.0K | 1.56M | +7% | +$385.0K |
| DT | 2025-06-24 | 2025-06-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | S - Sale+OE | $11.45 | -100.0K | 1.46M | -6% | -$1.15M |
| DM | 2025-06-04 | 2025-06-02+ | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | S - Sale+OE | $11.15 | -1.00M | 1.24M | -45% | -$11.15M |
| DM | 2025-06-04 | 2025-06-02+ | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | M - OptEx | $3.85 | +1.39M | 1.68M | +474% | +$5.33M |
| DT | 2025-05-22 | 2025-05-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | M - OptEx | $3.85 | +100.0K | 1.18M | +9% | +$385.0K |
| DT | 2025-05-22 | 2025-05-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | S - Sale+OE | $10.95 | -100.0K | 1.08M | -8% | -$1.09M |
| DT | 2025-05-22 | 2025-05-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | F - Tax | $11.04 | -39.1K | 1.08M | -4% | -$432.2K |
| DT | 2025-04-22 | 2025-04-21 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | S - Sale+OE | $10.22 | -100.0K | 1.12M | -8% | -$1.02M |
| DT | 2025-04-22 | 2025-04-21 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | M - OptEx | $3.85 | +100.0K | 1.22M | +9% | +$385.0K |
| DT | 2025-04-22 | 2025-04-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | F - Tax | $10.15 | -10.9K | 1.12M | -1.0% | -$111.1K |
| DT | 2025-03-24 | 2025-03-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | F - Tax | $10.97 | -10.9K | 875.0K | -1% | -$120.1K |
| DMT | 2025-03-24 | 2025-03-20+ | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | M - OptEx | $3.85 | +1.00M | 1.56M | +179% | +$3.86M |
| DMT | 2025-03-24 | 2025-03-20+ | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | S - Sale+OE | $10.92 | -750.0K | 1.13M | -40% | -$8.19M |
| D | 2025-02-24 | 2025-02-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | F - Tax | $10.72 | -10.9K | 885.9K | -1% | -$117.3K |
| D | 2025-02-24 | 2025-02-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | S - Sale+OE | $10.65 | -100.0K | 896.9K | -10% | -$1.06M |
| D | 2025-02-24 | 2025-02-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | M - OptEx | $3.85 | +100.0K | 996.9K | +11% | +$385.0K |
| DM | 2025-02-14 | 2025-02-12+ | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | S - Sale+OE | $10.47 | -435.4K | 732.3K | -37% | -$4.56M |
| DM | 2025-02-14 | 2025-02-12+ | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | M - OptEx | $3.85 | +600.0K | 1.03M | +139% | +$2.31M |
| DT | 2025-01-22 | 2025-01-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | F - Tax | $11.15 | -8,682 | 732.3K | -1% | -$96.8K |
| DT | 2025-01-22 | 2025-01-21 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | S - Sale+OE | $11.28 | -100.0K | 732.3K | -12% | -$1.13M |
| DT | 2025-01-22 | 2025-01-21 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | M - OptEx | $3.85 | +100.0K | 832.3K | +14% | +$385.0K |
| DM | 2024-12-31 | 2024-12-27+ | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | S - Sale+OE | $11.68 | -354.6K | 741.0K | -32% | -$4.14M |
| DM | 2024-12-31 | 2024-12-27+ | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | M - OptEx | $3.85 | +500.0K | 918.7K | +119% | +$1.93M |
| DT | 2024-12-26 | 2024-12-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | F - Tax | $11.57 | -10.9K | 595.6K | -2% | -$126.6K |
| DT | 2024-12-26 | 2024-12-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | S - Sale+OE | $11.49 | -100.0K | 595.6K | -14% | -$1.15M |
| DT | 2024-12-26 | 2024-12-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | M - OptEx | $3.85 | +100.0K | 695.6K | +17% | +$385.0K |
| DT | 2024-11-22 | 2024-11-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | S - Sale+OE | $11.32 | -100.0K | 606.5K | -14% | -$1.13M |
| DT | 2024-11-22 | 2024-11-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | M - OptEx | $3.85 | +100.0K | 706.5K | +16% | +$385.0K |
| DT | 2024-11-22 | 2024-11-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | F - Tax | $11.49 | -10.9K | 606.5K | -2% | -$125.8K |
| D | 2024-10-22 | 2024-10-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | F - Tax | $11.92 | -10.9K | 617.5K | -2% | -$130.5K |
| D | 2024-10-22 | 2024-10-21 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | S - Sale+OE | $11.65 | -100.0K | 617.5K | -14% | -$1.17M |
| D | 2024-10-22 | 2024-10-21 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | M - OptEx | $3.85 | +100.0K | 717.5K | +16% | +$385.0K |
| T | 2024-09-24 | 2024-09-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | F - Tax | $11.97 | -10.9K | 628.4K | -2% | -$131.0K |
| T | 2024-08-22 | 2024-08-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | F - Tax | $11.48 | -10.9K | 639.4K | -2% | -$125.7K |
| D | 2024-07-30 | 2024-07-26 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | A - Grant | $0.00 | +204.0K | 650.3K | +46% | $0 |
| T | 2024-07-25 | 2024-07-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | F - Tax | $11.00 | -10.9K | 446.3K | -2% | -$120.4K |
| T | 2024-06-24 | 2024-06-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | F - Tax | $10.80 | -10.9K | 457.3K | -2% | -$118.2K |
| T | 2024-05-22 | 2024-05-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | F - Tax | $11.37 | -16.0K | 468.2K | -3% | -$182.0K |
| T | 2024-04-23 | 2024-04-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | F - Tax | $10.46 | -16.0K | 484.2K | -3% | -$167.4K |
| T | 2024-03-22 | 2024-03-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | F - Tax | $10.01 | -16.0K | 500.2K | -3% | -$160.2K |
| T | 2024-02-22 | 2024-02-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | F - Tax | $11.54 | -16.0K | 516.2K | -3% | -$184.7K |
| DT | 2024-02-09 | 2024-02-09 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | M - OptEx | $3.85 | +97.0K | 629.2K | +18% | +$373.3K |
| DT | 2024-02-09 | 2024-02-09 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | S - Sale+OE | $10.92 | -97.0K | 532.2K | -15% | -$1.06M |
| T | 2024-01-23 | 2024-01-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | F - Tax | $10.35 | -12.4K | 532.2K | -2% | -$128.1K |
| T | 2023-12-22 | 2023-12-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | F - Tax | $9.96 | -16.0K | 544.6K | -3% | -$159.4K |
| T | 2023-11-27 | 2023-11-22 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | J - Other | $8.68 | -16.5K | 560.6K | -3% | -$143.6K |
| T | 2023-10-26 | 2023-10-24 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | J - Other | $8.99 | -18.3K | 577.1K | -3% | -$164.2K |
| DMT | 2023-10-04 | 2023-10-02+ | ROIV | Roivant Sciences Ltd. | Venker Eric | COO | S - Sale+OE | $10.43 | -1.20M | 595.4K | -67% | -$12.52M |
| DMT | 2023-10-04 | 2023-10-02+ | ROIV | Roivant Sciences Ltd. | Venker Eric | COO | M - OptEx | $3.85 | +1.20M | 748.4K | New | +$4.62M |
| D | 2023-09-29 | 2023-09-27 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | M - OptEx | $3.85 | +500.0K | 1.10M | +84% | +$1.93M |
| D | 2023-09-29 | 2023-09-27 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | S - Sale+OE | $13.02 | -500.0K | 595.4K | -46% | -$6.51M |
| 2023-09-26 | 2023-09-22 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | J - Other | $10.19 | -16.4K | 595.4K | -3% | -$167.3K | |
| D | 2023-09-12 | 2023-09-08 | ROIV | Roivant Sciences Ltd. | Venker Eric | COO | M - OptEx | $3.85 | +106.4K | 718.2K | +17% | +$409.8K |
Purchase Sale Sale after option exercise All abbreviations